Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools
- PMID: 24800237
- PMCID: PMC3996932
- DOI: 10.1155/2014/512831
Human pluripotent stem cell-derived cardiomyocytes as research and therapeutic tools
Abstract
Human pluripotent stem cells (hPSCs), namely, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), with their ability of indefinite self-renewal and capability to differentiate into cell types derivatives of all three germ layers, represent a powerful research tool in developmental biology, for drug screening, disease modelling, and potentially cell replacement therapy. Efficient differentiation protocols that would result in the cell type of our interest are needed for maximal exploitation of these cells. In the present work, we aim at focusing on the protocols for differentiation of hPSCs into functional cardiomyocytes in vitro as well as achievements in the heart disease modelling and drug testing on the patient-specific iPSC-derived cardiomyocytes (iPSC-CMs).
References
-
- Nichols M, Townsend N, Scarborough P, Rayner M. European cardiovascular disease statistics 4th edition 2012: EuroHeart II. European Heart Journal. 2013;34(39)3007 - PubMed
-
- Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annual Review of Physiology. 2009;72:19–44. - PubMed
-
- Kajstura J, Gurusamy N, Ogórek B, et al. Myocyte turnover in the aging human heart. Circulation Research. 2010;107(11):1374–1386. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
